Kent Kresa to Retire from MannKind’s Board of Directors; Steven B. Binder to be Appointed to the Board

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Kent Kresa has decided to retire from MannKind’s Board of Directors effective September 30, 2024. In addition, the Board of Directors has appointed Steven B. Binder to the Board, also effective September 30, 2024.

Kresa, who has served on MannKind’s Board of Directors since June 2004, was Chairman from 2016 until December 2020. Upon his retirement from the MannKind Board, Mr. Kresa will continue to be associated with the company in the capacity of Chairman Emeritus.

Binder previously served as MannKind’s Chief Financial Officer from July 2017 until April 2024 and currently serves as Executive Vice President, Special Projects. Mr. Binder will remain in that role until he joins the Board of Directors on September 30, 2024, after which he will no longer be an employee of the Company.

“We are sincerely grateful for two decades of invaluable leadership that Kent has provided the Board of Directors,” said James S. Shannon, Chairman of the Board. “We are looking forward to Steve joining the Board as he was instrumental in providing financial stewardship to MannKind during his tenure and helped bring MannKind into its current era with multiple revenue streams and healthy pipeline progression.”

With the addition of Binder, there will remain nine total members of the MannKind Board of Directors.

About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

MANNKIND is a registered trademark of MannKind Corporation.

CONTACT: For MannKind:
Christie Iacangelo
Corporate Communications
(818) 292-3500
Email: media@mnkd.com

Investor Relations
(818) 661-5000
Email: ir@mnkd.com